CytoMed Therapeutics Limited (GDTC)
SG — Healthcare Sector
Automate Your Wheel Strategy on GDTC
With Tiblio's Option Bot, you can configure your own wheel strategy including GDTC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GDTC
- Rev/Share 0.0311
- Book/Share 0.481
- PB 5.6311
- Debt/Equity 0.0685
- CurrentRatio 5.8074
- ROIC -0.4324
- MktCap 31446348.0
- FreeCF/Share -0.3179
- PFCF -8.3765
- PE -9.4469
- Debt/Assets 0.0586
- DivYield 0
- ROE -0.5472
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About CytoMed Therapeutics Limited (GDTC)
- IPO Date 2023-04-14
- Website https://w2.cytomed.sg
- Industry Biotechnology
- CEO Chee Kong Choo
- Employees 43
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.